• The PADCEV was evaluated in P-II EV-201 Trial to evaluate 125 patients locally advanced or metastatic urothelial cancer who received who received prior treatment with a PD-1 or PD-L1 inhibitor and a Pt-based CT
• The study resulted in ORR 44%- CR 12% leading no cancer detection at time of assessment- PR 32% meaning a decrease in tumor size or extent of cancer in the body- DoR 7.6 mos.
• PADCEV is a novel ADC directed against Nectin-4 a protein located on the surface of cells and highly expressed in bladder cancer and is currently evaluated in P-III EV-301Trial

Click here to read full press release/ article | Ref: Astellas | Image: Astellas